ZYNE Zynerba Pharmaceuticals

Zynerba Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference

Zynerba Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference

DEVON, Pa., April 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 19th Annual Needham Virtual Healthcare Conference. The presentation will take place on Wednesday April 15, 2020 at 2:50PM ET. This meeting is being held virtually, and a live webcast of the presentation will be accessible on the Investor Relations page of

About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at and follow us on Twitter at @ZynerbaPharma.  

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations.  These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at . Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Contact

William Roberts, Vice President, Investor Relations and Corporate Communications

Zynerba Pharmaceuticals

484.581.7489

 

EN
10/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zynerba Pharmaceuticals

 PRESS RELEASE

Important Information for Zynerba Pharmaceuticals Stockholders to Tend...

Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer (the “Offer”) by Harmony Biosciences Holdings, Inc. (“Harmony”) and its wholly owned subsidiary, Xylophone Acquisition Corp. (“Purchaser”), to purc...

 PRESS RELEASE

Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before ...

Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. (“Harmony”). Fellow Zynerba Pharmaceuticals Stockholders, We urge you to promptly tender your shares in response to the pending tender...

 PRESS RELEASE

Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeti...

Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting Annual Meeting to Reconvene on August 25, 2023 at 9:00 a.m. EDT DEVON, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the new date for the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting”) is August 25, 2023 at 9:00 a.m. EDT in order to provide stockholders additional time to consider and vote on Proposal...

 PRESS RELEASE

Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeti...

Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting Annual Meeting to Reconvene on August 11, 2023 at 9:00 a.m. EDT DEVON, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the new date for the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting”) is August 11, 2023 at 9:00 a.m. EDT in order to provide stockholders additional time to consider and vote on Proposal...

 PRESS RELEASE

Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meetin...

Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting Annual Meeting Reconvened and Adjourned Without Conducting Business Meeting to Reconvene on July 27, 2023 at 9:00 am EDT DEVON, Pa., June 28, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting”) was reconvened and then adjourned, without conducting any business, in order t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch